查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2067809

2026-2034年全球非結核分枝桿菌治療市場規模、佔有率、趨勢和成長分析報告

Global Nontuberculous Mycobacterium Treatment Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 230 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球非結核分枝桿菌治療市場預計將從2025年的102.4億美元成長至2034年的137.5億美元，2026年至2034年的複合年成長率（CAGR）為3.33%。該市場日益重要的原因在於非結核分枝桿菌感染疾病的盛行率不斷上升以及人們對呼吸系統健康意識的增強。這些感染疾病主要影響免疫力者和患有基礎肺部疾病的人群，因此對有效治療方法的需求不斷成長。診斷能力的提升也有助於更快地識別和治療這些感染疾病。

推動這一市場發展的因素包括醫療保健支出不斷成長、抗菌療法的進步以及針對感染疾病的研究活動日益增多。醫療服務提供者正著重強調早期診斷和標靶治療策略，以改善患者預後。醫護人員和病患意識的不斷提高，也進一步促進了各種醫療機構對專業治療方法的採用。

鑑於製藥公司持續投資於創新治療方法和臨床研究，前景依然光明。精準醫療的進步、診斷技術的改進以及醫療保健覆蓋範圍的擴大，預計將創造新的成長機會。對感染疾病控制和以患者為中心的護理的日益重視，將支持非結核分枝桿菌治療市場的長期發展。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的主要促進因素、阻礙因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分根據產品類型、應用、最終用戶和地區將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為指定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別預期的未來趨勢。

區域分析：這包括對主要地理區域的市場表現進行全面檢驗，確定高成長地區和區域趨勢，以更深入地了解區域市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區分析、競爭對手分析、客製化資料點或針對特定細分市場的洞察，從而更有效地支援策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章 全球非結核分枝桿菌治療市場：依藥物類別分類

  • 市場分析、洞察與預測
  • 大環內酯類
  • 利福平
  • Aminoglycosides抗生素
  • 其他

第5章 全球非結核分枝桿菌治療市場：依給藥途徑分類

  • 市場分析、洞察與預測
  • 口服
  • 腸外
  • 其他

第6章 全球非結核分枝桿菌治療市場：依通路分類

  • 市場分析、洞察與預測
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第7章 全球非結核分枝桿菌治療市場：依地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第8章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第9章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Pfizer Inc
    • Johnson & Johnson
    • Merck & Co. Inc
    • AbbVie Inc
    • Bayer AG
    • Novartis AG
    • Sanofi SA
    • Bristol Myers Squibb
    • AstraZeneca Plc
    • Abbott Laboratories
    • GlaxoSmithKline Plc
    • Takeda Pharmaceutical Company
    • Eli Lilly And Company
    • CH Boehringer Sohn AG & Co. KG
    • Teva Pharmaceutical Industries Ltd
簡介目錄
Product Code: VMR11216905

The global nontuberculous mycobacterium treatment market size is expected to reach USD 13.75 Billion in 2034 from USD 10.24 Billion in 2025, growing at a CAGR of 3.33 during 2026-2034.This market has gained importance due to the increasing prevalence of nontuberculous mycobacterial infections and growing awareness of respiratory health. These infections primarily affect individuals with weakened immune systems or underlying lung conditions, creating a rising demand for effective treatment options. Improvements in diagnostic capabilities have also contributed to increased identification and management of such infections.

The market is driven by growing healthcare expenditures, advancements in antimicrobial therapies, and expanding research efforts focused on infectious diseases. Healthcare providers are emphasizing early diagnosis and targeted treatment strategies to improve patient outcomes. Rising awareness among medical professionals and patients has further supported the adoption of specialized treatment regimens across healthcare settings.

Future prospects remain promising as pharmaceutical companies continue investing in innovative therapies and clinical research. Advances in precision medicine, improved diagnostic technologies, and expanded healthcare access are expected to create new growth opportunities. Increasing focus on infectious disease management and patient-centered care will likely support long-term expansion of the nontuberculous mycobacterium treatment market.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Drug Class

  • Macrolides
  • Rifampin
  • Aminoglycoside
  • Other

By Route Of Administration

  • Oral
  • Parenteral
  • Other

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

COMPANIES PROFILED

  • Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol Myers Squibb, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Eli Lilly and Company, C.H. Boehringer Sohn AG & Co. KG, Teva Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL NONTUBERCULOUS MYCOBACTERIUM TREATMENT MARKET: BY DRUG CLASS 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Drug Class
  • 4.2. Macrolides Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Rifampin Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Aminoglycoside Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Other Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL NONTUBERCULOUS MYCOBACTERIUM TREATMENT MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Route Of Administration
  • 5.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Parenteral Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Other Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL NONTUBERCULOUS MYCOBACTERIUM TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Distribution Channel
  • 6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL NONTUBERCULOUS MYCOBACTERIUM TREATMENT MARKET: BY REGION 2022-2034 (USD MN)

  • 7.1. Regional Outlook
  • 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.2.1 By Drug Class
    • 7.2.2 By Route Of Administration
    • 7.2.3 By Distribution Channel
    • 7.2.4 United States
    • 7.2.5 Canada
    • 7.2.6 Mexico
  • 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.3.1 By Drug Class
    • 7.3.2 By Route Of Administration
    • 7.3.3 By Distribution Channel
    • 7.3.4 United Kingdom
    • 7.3.5 France
    • 7.3.6 Germany
    • 7.3.7 Italy
    • 7.3.8 Russia
    • 7.3.9 Rest Of Europe
  • 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.4.1 By Drug Class
    • 7.4.2 By Route Of Administration
    • 7.4.3 By Distribution Channel
    • 7.4.4 India
    • 7.4.5 Japan
    • 7.4.6 South Korea
    • 7.4.7 Australia
    • 7.4.8 South East Asia
    • 7.4.9 Rest Of Asia Pacific
  • 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.5.1 By Drug Class
    • 7.5.2 By Route Of Administration
    • 7.5.3 By Distribution Channel
    • 7.5.4 Brazil
    • 7.5.5 Argentina
    • 7.5.6 Peru
    • 7.5.7 Chile
    • 7.5.8 Rest of Latin America
  • 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.6.1 By Drug Class
    • 7.6.2 By Route Of Administration
    • 7.6.3 By Distribution Channel
    • 7.6.4 Saudi Arabia
    • 7.6.5 UAE
    • 7.6.6 Israel
    • 7.6.7 South Africa
    • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

  • 8.1. Recent Developments
  • 8.2. Company Categorization
  • 8.3. Supply Chain & Channel Partners (based on availability)
  • 8.4. Market Share & Positioning Analysis (based on availability)
  • 8.5. Vendor Landscape (based on availability)
  • 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL NONTUBERCULOUS MYCOBACTERIUM TREATMENT INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Company Profiles
    • 9.2.1 Pfizer Inc
    • 9.2.2 Johnson & Johnson
    • 9.2.3 Merck & Co. Inc
    • 9.2.4 AbbVie Inc
    • 9.2.5 Bayer AG
    • 9.2.6 Novartis AG
    • 9.2.7 Sanofi S.A
    • 9.2.8 Bristol Myers Squibb
    • 9.2.9 AstraZeneca Plc
    • 9.2.10 Abbott Laboratories
    • 9.2.11 GlaxoSmithKline Plc
    • 9.2.12 Takeda Pharmaceutical Company
    • 9.2.13 Eli Lilly And Company
    • 9.2.14 C.H. Boehringer Sohn AG & Co. KG
    • 9.2.15 Teva Pharmaceutical Industries Ltd